Dataset Information

The small heat shock protein Alpha-Crystallin B shows neuroprotective properties in a glaucoma animal model

ABSTRACT: Aim of this study was the evaluation of Alpha-crystallin B and its potential neuroprotective properties in an experimentalanimal model of glaucoma with subsequent analysis of possible altered downstream markers in a complex mass spectrometric approach.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Rattus Norvegicus (rat)

TISSUE(S): Retina

DISEASE(S): Glaucoma

SUBMITTER: Fabian Anders

LAB HEAD: Dr. Verena Prokosch-Willing

PROVIDER: PXD007751 | Pride | 2017-11-21

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20170630_QEP1_EXT_CF_0255_rn_PR_LFQ_120.raw	Raw
	20170630_QEP1_EXT_CF_0256_rn_PR_LFQ_120.raw	Raw
	20170630_QEP1_EXT_CF_0257_rn_PR_LFQ_120.raw	Raw
	20170630_QEP1_EXT_CF_0258_rn_PR_LFQ_120.raw	Raw
	20170630_QEP1_EXT_CF_0259_rn_PR_LFQ_120.raw	Raw

Items per page:

1 - 5 of 9

Publications

The Small Heat Shock Protein α-Crystallin B Shows Neuroprotective Properties in a Glaucoma Animal Model.

Anders Fabian F Liu Aiwei A Mann Carolina C Teister Julia J Lauzi Jasmin J Thanos Solon S Grus Franz H FH Pfeiffer Norbert N Prokosch Verena V

International journal of molecular sciences 20171114 11

Glaucoma is a neurodegenerative disease that leads to irreversible retinal ganglion cell (RGC) loss and is one of the main causes of blindness worldwide. The pathogenesis of glaucoma remains unclear, and novel approaches for neuroprotective treatments are urgently needed. Previous studies have revealed significant down-regulation of α-crystallin B as an initial reaction to elevated intraocular pressure (IOP), followed by a clear but delayed up-regulation, suggesting that this small heat-shock pr ...[more]

PMID: 29135941

Similar Datasets

Project description:Glaucoma is a group of optic neuropathies characterized by the progressive degeneration of retinal ganglion cells (RGCs) as well as their axons leading to irreversible loss of sight. Medical management of the intraocular pressure (IOP) still represents the gold standard in glaucoma therapy, which only manages a risk factor and does not directly address the neurodegenerative component of this eye disease. Recently, our group showed that antibody derived immunopeptides (encoding complementarity-determining regions, CDRs) provide attractive glaucoma medication candidates and directly interfere its pathogenic mechanisms by different modes of action. In accordance with these findings, the present study showed the synthetic CDR2 peptide (INSDGSSTSYADSVK) significantly increased the RGCs viability in vitro in a concentration-dependent manner (p < 0.05 using a CDR2 concentration of 50 µg/mL). Employing state-of the-art immunoprecipitation experiments, we confirmed that synthetic CDR2 exhibited a high affinity towards the retinal target protein histone H3.1 (HIST1H3A) (p < 0.001 and log2 fold change > 3). Furthermore, virtual docking analyses predicted potential CDR2-specific binding regions of HIST1H3A, which might represent essential PTM sites for epigenetic regulations. Quantitative MS analysis revealed that 39 proteins were significantly changed between CDR2-treated and untreated control retinae (p < 0.05). An up-regulation of proteins involved in the energy production (e.g., ATP5F1B and MT-CO2) as well as the regulatory ubiquitin proteasome system (e.g., PSMC5) was induced by the synthetic CDR2 peptide. On the other hand, metabolic key enzymes (e.g., DDAH1 and MAOB) as well as ER stress-related proteins (e.g., SEC22B and VCP) were found with low abundancy in CDR2-treated retinae and were also partially confirmed by microarray technology. Based on these findings, it can be hypothesized that the specific protein-peptide interaction influences the regulatory epigenetic function of HIST1H3A promoting the neuroprotective mechanism on RGCs in vitro. It also might serve as basis for a synergistic immunotherapy of glaucoma in the future.